253 related articles for article (PubMed ID: 30513017)
1. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
Dillon C; Guarascio AJ; Covvey JR
Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
[TBL] [Abstract][Full Text] [Related]
2. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
[TBL] [Abstract][Full Text] [Related]
3. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
Veve MP; Wagner JL
Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
[TBL] [Abstract][Full Text] [Related]
5. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.
Lee YR; Jacobs KL
Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486
[TBL] [Abstract][Full Text] [Related]
6. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
Chahine EB; Sucher AJ
Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
[TBL] [Abstract][Full Text] [Related]
7. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
Tang HJ; Wang JH; Lai CC
Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
[TBL] [Abstract][Full Text] [Related]
8. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
Watkins RR; File TM
Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
[TBL] [Abstract][Full Text] [Related]
9. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).
Paukner S; Gelone SP; Arends SJR; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670415
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic.
Covvey JR; Guarascio AJ
J Intern Med; 2022 Jan; 291(1):51-63. PubMed ID: 34425035
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
[TBL] [Abstract][Full Text] [Related]
13. Lefamulin (Xenleta) for community-acquired bacterial pneumonia.
Med Lett Drugs Ther; 2019 Sep; 61(1581):145-148. PubMed ID: 31599865
[No Abstract] [Full Text] [Related]
14. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.
Wicha WW; Strickmann DB; Paukner S
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii11-iii18. PubMed ID: 30949707
[TBL] [Abstract][Full Text] [Related]
16. 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.
Paukner S; Mendes RE; Arends SJR; Gassner G; Gelone SP; Sader HS
J Antimicrob Chemother; 2024 Feb; 79(2):360-369. PubMed ID: 38113528
[TBL] [Abstract][Full Text] [Related]
17. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
Falcó V; Burgos J; Almirante B
Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
[TBL] [Abstract][Full Text] [Related]
18. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin.
Wang H; Charles CV
Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia.
Perry W; Golan Y
Future Microbiol; 2019 Jul; 14():927-939. PubMed ID: 31333062
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
